This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
5 ETF Areas That Underperformed in May
by Sanghamitra Saha
Wall Street has experienced a robust upswing in May but few investing areas have fallen short of the broader market rally.
Cannabis ETF (MSOS) Hits New 52-Week High
by Yashwardhan Jain
This Cannabis ETF hits a new 52-week high. Are more gains in store for this ETF?
Top ETF Stories of March to Be Watched in April
by Sanghamitra Saha
Wall Street delivered a decent performance in March. With rates rising to start April, let's look at the key ETF stories of March that may hit headlines in April too.
Top ETF Stories of Q1 of 2024
by Sanghamitra Saha
The S&P 500 just closed out best first quarter since 2019.
4 Best ETF Areas of Q1
by Sanghamitra Saha
Wall Street is poised to conclude the first quarter with robust gains due to a likely dovish Fed and robust economic as well as earnings growth.
Is Rescheduling a Certainty for Cannabis? ETFs That Surge
by Sanghamitra Saha
In a White House meeting, Vice President Kamala Harris this week urged the DEA to expedite the rescheduling of marijuana. President Biden also lately talked about ongoing efforts to review the federal classification of marijuana, hinting at his commitment to potential reforms
5 Best ETF Areas of Last Week
by Sanghamitra Saha
Wall Street delivered a downbeat performance last week.
Cannabis ETFs Jump on Imminent Rescheduling News
by Sweta Killa
Cannabis stocks & ETFs jumped on Mar 15 after a prominent hedge fund manager suggested that regulators will soon reclassify marijuana as a less dangerous drug.
Marijuana ETFs Breezing Past S&P 500: More Growth Ahead?
by Sanghamitra Saha
Cannabis stocks soared this year after the Department of Health and Human Services asked the US Drug Enforcement Administration to start reviewing its classification of cannabis from Schedule I to Schedule III. Positive developments are happening in Germany also.
Cannabis ETFs Outperform in January
by Sweta Killa
The cannabis industry has been performing well this year after the US Drug Enforcement Administration started reviewing the potential reclassification of cannabis from Schedule I to Schedule III.